RxDoctor Payments DataLook up a doctor →

Christopher Rhyne, MD

Family Medicine · Louisville, KYNPI 1093129835

Payments from drug & device makers

$1,047,352in general payments, 2019–2025

Across 1,713 payments — averaging $611.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$612K
  • Axsome Therapeutics, Inc.$82K
  • Lundbeck LLC$69K
  • H. Lundbeck A S$61K
  • Amgen$54K
  • Biohaven Pharmaceutical Holding Company Ltd.$35K
  • plus $134K from 33 others
$1,532in research payments, 2019–2025

Across 1 payment — averaging $1532.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$2K

What the payments were for

  • Consulting fees$138,11415%
  • Speaking & faculty fees$674,00872%
  • Grants$880%
  • Travel & lodging$92,90310%
  • Food & beverage$27,7163%
  • Education$2880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047,352 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$27,975
Medicare patients
83
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate58$95,664
QuliptaAtogepant68$82,994
UbrelvyUbrogepant25$36,255
Aimovig AutoinjectorErenumab-Aooe37$28,300
Ajovy AutoinjectorFremanezumab-Vfrm29$28,212
Diclofenac Potassium83$4,458
Amitriptyline Hcl303$3,087
Carbamazepine ErCarbamazepine23$2,756
Pregabalin45$1,465
RizatriptanRizatriptan Benzoate110$1,179
Gabapentin66$831
Ondansetron Hcl86$809
Propranolol Hcl ErPropranolol Hcl22$766
Levetiracetam ErLevetiracetam34$631
Celecoxib19$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$611,719$119,24993 claims
PfizerNurtec Odt$29,559$95,66458 claims
Upsher-smith Laboratories LLCTopiramate$360$45234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →